Staszewski S - Search Results

1

CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.

Miller V, Staszewski S, Sabin C, Carlebach A, Rottmann C, Weidmann E, Rabenau H, Hill A, Lepri AC, Phillips AN. Miller V, et al. Among authors: staszewski s. J Infect Dis. 1999 Aug;180(2):530-3. doi: 10.1086/314890. J Infect Dis. 1999. PMID: 10395876

2

Virological response to protease inhibitor therapy in an HIV clinic cohort.

Staszewski S, Miller V, Sabin C, Carlebach A, Berger AM, Weidmann E, Helm EB, Hill A, Phillips A. Staszewski S, et al. AIDS. 1999 Feb 25;13(3):367-73. doi: 10.1097/00002030-199902250-00009. AIDS. 1999. PMID: 10199227

3

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.

Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, Leder T, Berger A, Weidemann E, Hill A, Phillips A. Staszewski S, et al. AIDS. 1999 May 28;13(8):951-6. doi: 10.1097/00002030-199905280-00011. AIDS. 1999. PMID: 10371176

4

Resistance profiles in patients with viral rebound on potent antiretroviral therapy.

Cozzi Lepri A, Sabin CA, Staszewski S, Hertogs K, Müller A, Rabenau H, Phillips AN, Miller V. Cozzi Lepri A, et al. Among authors: staszewski s. J Infect Dis. 2000 Mar;181(3):1143-7. doi: 10.1086/315301. J Infect Dis. 2000. PMID: 10720543

5

The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load.

Miller V, Sabin CA, Phillips AN, Rottmann C, Rabenau H, Weidmann E, Rickerts V, Findhammer S, Helm EB, Staszewski S. Miller V, et al. Among authors: staszewski s. AIDS. 2000 Sep 29;14(14):2129-36. doi: 10.1097/00002030-200009290-00009. AIDS. 2000. PMID: 11061654 Clinical Trial.

6

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.

Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, Larder B, Lutz T, Gute P, Weidmann E, Rabenau H, Phillips A, Staszewski S. Miller V, et al. Among authors: staszewski s. AIDS. 2000 Dec 22;14(18):2857-67. doi: 10.1097/00002030-200012220-00007. AIDS. 2000. PMID: 11153667

7

Mega-HAART: preliminary results and correlation with baseline resistance.

Rottmann C, Miller V, Staszewski S. Rottmann C, et al. Among authors: staszewski s. Antivir Ther. 1999;4 Suppl 3:93-4. Antivir Ther. 1999. PMID: 16021879

8

HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors.

Staszewski S, DeMasi R, Hill AM, Dawson D. Staszewski S, et al. AIDS. 1998 Oct 22;12(15):1991-7. doi: 10.1097/00002030-199815000-00010. AIDS. 1998. PMID: 9814867

9

Rebound of HIV-1 viral load after suppression to very low levels.

Staszewski S, Miller V, Sabin C, Berger A, Hill AM, Phillips AN. Staszewski S, et al. AIDS. 1998 Dec 3;12(17):2360. AIDS. 1998. PMID: 9863886 No abstract available.

10

Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users.

Staszewski S, Haberl A, Gute P, Nisius G, Miller V, Carlebach A. Staszewski S, et al. Antivir Ther. 1998;3 Suppl 4:55-6. Antivir Ther. 1998. PMID: 10723511 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

251 results

Search Page

Filters